A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce glucose
levels in patients with type 2 diabetes mellitus since 2005. This meta-analysis discusses the …
levels in patients with type 2 diabetes mellitus since 2005. This meta-analysis discusses the …
[HTML][HTML] Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
AJ Scheen - Diabetes Epidemiology and Management, 2023 - Elsevier
Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and chronic kidney
disease (CKD) are major complications of type 2 diabetes (T2DM). The objectives of …
disease (CKD) are major complications of type 2 diabetes (T2DM). The objectives of …
Longitudinal assessment of coronary plaque regression related to sodium–glucose cotransporter-2 inhibitor using coronary computed tomography angiography
T Zhang, X Gao, T Chen, H Zhang, X Zhang… - Cardiovascular …, 2024 - Springer
Abstract Background Sodium–Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral
drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits …
drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits …
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal
disorders is challenging because of the potential for interference with the absorption of …
disorders is challenging because of the potential for interference with the absorption of …
The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction
K Iwakura, T Onishi, A Okamura, Y Koyama… - Scientific Reports, 2024 - nature.com
The coexistence of heart failure is frequent and associated with higher mortality in patients
with type 2 diabetes (T2DM), and its management is a critical issue. The WATCH-DM risk …
with type 2 diabetes (T2DM), and its management is a critical issue. The WATCH-DM risk …
When cardiovascular medicines should be discontinued
KA Krychtiuk, BJ Gersh, JB Washam… - European Heart …, 2024 - academic.oup.com
An integral component of the practice of medicine is focused on the initiation of medications,
based on clinical practice guidelines and underlying trial evidence, which usually test the …
based on clinical practice guidelines and underlying trial evidence, which usually test the …
Diabetes mellitus in acute coronary syndrome
PK Stampouloglou, A Anastasiou, E Bletsa, S Lygkoni… - Life, 2023 - mdpi.com
The global prevalence of diabetes mellitus (DM) has led to a pandemic, with significant
microvascular and macrovascular complications including coronary artery disease (CAD) …
microvascular and macrovascular complications including coronary artery disease (CAD) …
LDL cholesterol variability impacts the prognosis of patients with chronic ischemic heart disease: a real-world Italian experience
P Faggiano, M Ruscica, S Bettari, A Cherubini… - Journal of Clinical …, 2023 - mdpi.com
Epidemiologic, genetic, and clinical intervention studies have indisputably shown that low-
density lipoprotein cholesterol (LDL-C) is causal in the development of atherosclerotic …
density lipoprotein cholesterol (LDL-C) is causal in the development of atherosclerotic …
Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020
KS Johansson, C Bülow, E Jimenez-Solem… - The Lancet Healthy …, 2023 - thelancet.com
Background The pharmacotherapeutic guidelines for type 2 diabetes have changed
considerably during the past decades. SGLT2 inhibitors and GLP-1 receptor agonists have …
considerably during the past decades. SGLT2 inhibitors and GLP-1 receptor agonists have …
Glycemic control and coronary stent failure in patients with type 2 diabetes mellitus
I Santos-Pardo, M Andersson Franko… - Journal of the American …, 2024 - jacc.org
Background The impact of glycemic control in the risk of stent failure in subjects with type 2
diabetes (T2D) is currently unknown. Objectives This study sought to study whether poor …
diabetes (T2D) is currently unknown. Objectives This study sought to study whether poor …